Published in Antimicrob Agents Chemother on January 01, 2003
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. Antimicrob Agents Chemother (2007) 3.08
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother (2009) 1.52
Plasmodium falciparum genotypes diversity in symptomatic malaria of children living in an urban and a rural setting in Burkina Faso. Malar J (2009) 1.43
Polymorphism in two merozoite surface proteins of Plasmodium falciparum isolates from Gabon. Malar J (2003) 1.15
Does the drug sensitivity of malaria parasites depend on their virulence? Malar J (2008) 1.11
Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria. Antimicrob Agents Chemother (2008) 1.10
Efficacy of chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in Honduras. Am J Trop Med Hyg (2013) 1.03
A molecular epidemiological study of var gene diversity to characterize the reservoir of Plasmodium falciparum in humans in Africa. PLoS One (2011) 0.98
Sulphadoxine/pyrimethamine versus amodiaquine for treating uncomplicated childhood malaria in Gabon: a randomized trial to guide national policy. Malar J (2008) 0.96
Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy. Antimicrob Agents Chemother (2010) 0.93
Genetic polymorphism of merozoite surface protein-1 and merozoite surface protein-2 in Plasmodium falciparum isolates from children in South of Benin. Parasite (2013) 0.84
In vitro antimalarial susceptibility and molecular markers of drug resistance in Franceville, Gabon. BMC Infect Dis (2012) 0.84
Amodiaquine-associated adverse effects after inadvertent overdose and after a standard therapeutic dose. Ghana Med J (2009) 0.80
Low prevalence of the molecular markers of Plasmodium falciparum resistance to chloroquine and sulphadoxine/pyrimethamine in asymptomatic children in Northern Benin. Malar J (2013) 0.80
Short course of quinine plus a single dose of sulfadoxine/pyrimethamine for Plasmodium falciparum malaria. Wien Klin Wochenschr (2006) 0.77
Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali. Malar J (2011) 0.76
Malaria in urban, semi-urban and rural areas of southern of Gabon: comparison of the Pfmdr 1 and Pfcrt genotypes from symptomatic children. Malar J (2016) 0.75
Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg (2000) 22.12
Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg (1995) 7.63
Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet (2002) 4.47
Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem Parasitol (1993) 3.99
Complex polymorphisms in an approximately 330 kDa protein are linked to chloroquine-resistant P. falciparum in Southeast Asia and Africa. Cell (1997) 3.98
Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol (2001) 3.84
Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet (1996) 3.40
Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem (1994) 3.34
Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc Natl Acad Sci U S A (1990) 3.24
Daily dynamics of Plasmodium falciparum subpopulations in asymptomatic children in a holoendemic area. Am J Trop Med Hyg (1997) 2.36
Structural diversity in the 45-kilodalton merozoite surface antigen of Plasmodium falciparum. Mol Biochem Parasitol (1990) 2.16
A simple and reliable method for estimating haemoglobin. Bull World Health Organ (1995) 1.94
Molecular analysis of recrudescent parasites in a Plasmodium falciparum drug efficacy trial in Gabon. Trans R Soc Trop Med Hyg (1998) 1.91
Rapid turnover of Plasmodium falciparum populations in asymptomatic individuals living in a high transmission area. Am J Trop Med Hyg (1996) 1.76
Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet (2001) 1.58
Amodiaquine remains effective for treating uncomplicated malaria in west and central Africa. Trans R Soc Trop Med Hyg (2000) 1.51
Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet (1996) 1.46
The comparative efficacy of chloroquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Trans R Soc Trop Med Hyg (2001) 1.45
Polymorphism of the alleles of the merozoite surface antigens MSA1 and MSA2 in Plasmodium falciparum wild isolates from Colombia. Mol Biochem Parasitol (1991) 1.44
Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med (1990) 1.36
Malaria transmission in a region of savanna-forest mosaic, Haut-Ogooué, Gabon. J Am Mosq Control Assoc (1999) 1.29
A cohort study of Plasmodium falciparum diversity during the dry season in Ndiop, a Senegalese village with seasonal, mesoendemic malaria. Trans R Soc Trop Med Hyg (2000) 1.26
Comparison of in vivo and in vitro tests of resistance in patients treated with chloroquine in Yaoundé, Cameroon. Bull World Health Organ (1999) 1.21
Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. Bull World Health Organ (2002) 1.21
In vivo efficacy study of amodiaquine and sulfadoxine/ pyrimethamine in Kibwezi, Kenya and Kigoma, Tanzania. Trop Med Int Health (2000) 1.10
Simultaneous determination of chloroquine, amodiaquine and their metabolites in human plasma, red blood cells, whole blood and urine by column liquid chromatography. J Chromatogr (1986) 1.09
A randomized trial of chloroquine, amodiaquine and pyrimethamine-sulphadoxine in Gambian children with uncomplicated malaria. Trop Med Int Health (1996) 1.05
A trial of Fansidar plus chloroquine or Fansidar alone for the treatment of uncomplicated malaria in Gambian children. Trans R Soc Trop Med Hyg (1998) 1.00
Chemoresistance of Plasmodium falciparum in the urban region of Yaounde, Cameroon. Part 2: Evaluation of the efficacy of amodiaquine and sulfadoxine-pyrimethamine combination in the treatment of uncomplicated Plasmodium falciparum malaria in Yaounde, Cameroon. Trop Med Int Health (2000) 0.95
Quantification of antimalarial drugs. II. Simultaneous measurement of dapsone, monoacetyldapsone and pyrimethamine in human plasma. J Chromatogr (1984) 0.88
Sulfadoxine-pyrimethamine for the treatment of Plasmodium falciparum malaria in Gabonese children. Trans R Soc Trop Med Hyg (2000) 0.88
Amodiaquine and sulfadoxine-pyrimethamine as treatment for chloroquine-resistant Plasmodium falciparum in Rwanda. Am J Trop Med Hyg (1988) 0.86
[Drug-resistant malaria: problems with its definition and technical approaches]. Sante (2000) 0.83
Economic prospects for a new antimalarial drug. Trans R Soc Trop Med Hyg (1994) 0.82
Evidence that recurrent Plasmodium falciparum infection is caused by recrudescence of resistant parasites. Am J Trop Med Hyg (1997) 0.82
The efficacy of pyrimethamine-sulfadoxine (Fansidar) in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children. Trans R Soc Trop Med Hyg (2000) 0.81
Malaria-treatment policies: when and how should they be changed? Ann Trop Med Parasitol (1999) 0.79
Quantification of antimalarial drugs. I. Simultaneous measurement of sulphadoxine, N4-acetylsulphadoxine and pyrimethamine in human plasma. J Chromatogr (1984) 0.78
The clinical spectrum of severe imported falciparum malaria in the intensive care unit: report of 188 cases in adults. Am J Respir Crit Care Med (2002) 2.79
Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar J (2009) 2.33
Multiplicity of Plasmodium falciparum infection in asymptomatic children in Senegal: relation to transmission, age and erythrocyte variants. Malar J (2008) 2.16
High level of var2csa transcription by Plasmodium falciparum isolated from the placenta. J Infect Dis (2005) 1.90
Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from africa by using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration. Antimicrob Agents Chemother (2006) 1.89
Congenital parasitic infections: a review. Acta Trop (2011) 1.88
Predictive factors of malaria in travelers to areas where malaria is endemic. Arch Intern Med (2002) 1.86
Severe imported falciparum malaria: a cohort study in 400 critically ill adults. PLoS One (2010) 1.86
Online analysis of in vitro resistance to antimalarial drugs through nonlinear regression. Comput Methods Programs Biomed (2010) 1.85
Coinfection with Plasmodium falciparum and schistosoma haematobium: protective effect of schistosomiasis on malaria in senegalese children? Am J Trop Med Hyg (2005) 1.82
Influence of the timing of malaria infection during pregnancy on birth weight and on maternal anemia in Benin. Am J Trop Med Hyg (2011) 1.80
Decreased in vitro susceptibility of Plasmodium falciparum isolates to artesunate, mefloquine, chloroquine, and quinine in Cambodia from 2001 to 2007. Antimicrob Agents Chemother (2010) 1.76
Epitope mapping and topographic analysis of VAR2CSA DBL3X involved in P. falciparum placental sequestration. PLoS Pathog (2006) 1.76
Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. J Infect Dis (2009) 1.75
Plasmodium falciparum clonal population dynamics during malaria treatment. J Infect Dis (2004) 1.74
Population genomics of the immune evasion (var) genes of Plasmodium falciparum. PLoS Pathog (2007) 1.74
Evaluation of the intra- and inter-specific genetic variability of Plasmodium lactate dehydrogenase. Malar J (2007) 1.71
Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. Microbes Infect (2006) 1.56
Invasion of Africa by a single pfcrt allele of South East Asian type. Malar J (2006) 1.51
Chimpanzee malaria parasites related to Plasmodium ovale in Africa. PLoS One (2009) 1.49
Hospitalization criteria in imported falciparum malaria. J Travel Med (2007) 1.45
The importance of the period of malarial infection during pregnancy on birth weight in tropical Africa. Am J Trop Med Hyg (2007) 1.44
Rapid dissemination of Plasmodium falciparum drug resistance despite strictly controlled antimalarial use. PLoS One (2007) 1.44
World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility. Malar J (2007) 1.41
[Rapid detection of malaria and P. falciparum chemoresistant genotypes in Mayotte, 2001]. Presse Med (2002) 1.41
Resistance to dihydroartemisinin. Emerg Infect Dis (2006) 1.40
Do African immigrants living in France have long-term malarial immunity? Am J Trop Med Hyg (2005) 1.39
Risk factors for imported fatal Plasmodium falciparum malaria, France, 1996-2003. Emerg Infect Dis (2007) 1.37
Parasitic co-infections: does Ascaris lumbricoides protect against Plasmodium falciparum infection? Am J Trop Med Hyg (2006) 1.37
Can treatment of malaria be restricted to parasitologically confirmed malaria? A school-based study in Benin in children with and without fever. Malar J (2010) 1.36
Variable adhesion abilities and overlapping antigenic properties in placental Plasmodium falciparum isolates. J Infect Dis (2004) 1.36
Combined deletions of pfhrp2 and pfhrp3 genes result in Plasmodium falciparum malaria false-negative rapid diagnostic test. J Clin Microbiol (2011) 1.34
Intermittent preventive treatment for the prevention of malaria during pregnancy in high transmission areas. Malar J (2007) 1.34
Confirmation of the protective effect of Ascaris lumbricoides on Plasmodium falciparum infection: results of a randomized trial in Madagascar. Am J Trop Med Hyg (2007) 1.32
Dramatically decreased therapeutic efficacy of chloroquine and sulfadoxine-pyrimethamine, but not mefloquine, in southern Benin. Trop Med Int Health (2007) 1.30
PfHRP2 and PfLDH antigen detection for monitoring the efficacy of artemisinin-based combination therapy (ACT) in the treatment of uncomplicated falciparum malaria. Malar J (2009) 1.29
Maternal anemia in Benin: prevalence, risk factors, and association with low birth weight. Am J Trop Med Hyg (2011) 1.27
Efficacy of intermittent preventive treatment versus chloroquine prophylaxis to prevent malaria during pregnancy in Benin. J Infect Dis (2008) 1.26
The role of the G6PD AEth376G/968C allele in glucose-6-phosphate dehydrogenase deficiency in the seerer population of Senegal. Haematologica (2006) 1.26
Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. J Antimicrob Chemother (2005) 1.23
The sickle cell trait is associated with enhanced immunoglobulin G antibody responses to Plasmodium falciparum variant surface antigens. J Infect Dis (2005) 1.23
Molecular markers of resistance to sulphadoxine-pyrimethamine during intermittent preventive treatment of pregnant women in Benin. Malar J (2011) 1.21
Prevention of malaria during pregnancy: assessing the effect of the distribution of IPTp through the national policy in Benin. Am J Trop Med Hyg (2011) 1.21
Plasmodium falciparum genotype population dynamics in asymptomatic children from Senegal. Microbes Infect (2006) 1.18
In vitro susceptibility to a new antimalarial organometallic analogue, ferroquine, of Plasmodium falciparum isolates from the Haut-Ogooué region of Gabon. J Antimicrob Chemother (2003) 1.17
DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy. J Antimicrob Chemother (2003) 1.16
High-throughput analysis of antimalarial susceptibility data by the WorldWide Antimalarial Resistance Network (WWARN) in vitro analysis and reporting tool. Antimicrob Agents Chemother (2013) 1.15
Severe imported Plasmodium falciparum malaria, France, 1996-2003. Emerg Infect Dis (2011) 1.15
Polymorphism in two merozoite surface proteins of Plasmodium falciparum isolates from Gabon. Malar J (2003) 1.15
Parallel evolution of adaptive mutations in Plasmodium falciparum mitochondrial DNA during atovaquone-proguanil treatment. Mol Biol Evol (2007) 1.13
Infections in infants during the first 12 months of life: role of placental malaria and environmental factors. PLoS One (2011) 1.12
Epidemiology of drug-resistant malaria in Republic of Congo: using molecular evidence for monitoring antimalarial drug resistance combined with assessment of antimalarial drug use. Trop Med Int Health (2005) 1.12
IL-12 producing monocytes and IFN-gamma and TNF-alpha producing T-lymphocytes are increased in placentas infected by Plasmodium falciparum. J Reprod Immunol (2006) 1.12
Prolonged Plasmodium falciparum infection in immigrants, Paris. Emerg Infect Dis (2008) 1.10
Baseline in vitro efficacy of ACT component drugs on Plasmodium falciparum clinical isolates from Mali. Int J Parasitol (2008) 1.09
Serological evaluation of Mycobacterium ulcerans antigens identified by comparative genomics. PLoS Negl Trop Dis (2010) 1.08
Relation between Plasmodium falciparum asymptomatic infection and malaria attacks in a cohort of Senegalese children. Malar J (2008) 1.07
First-trimester Plasmodium falciparum infections display a typical "placental" phenotype. J Infect Dis (2012) 1.07
Leishmania resistance to miltefosine associated with genetic marker. Emerg Infect Dis (2012) 1.07
Maternally transmitted antibodies to pregnancy-associated variant antigens on the surface of erythrocytes infected with Plasmodium falciparum: relation to child susceptibility to malaria. Am J Epidemiol (2003) 1.06
Malaria, from natural to supernatural: a qualitative study of mothers' reactions to fever (Dienga, Gabon). J Epidemiol Community Health (2004) 1.05
Demonstration of a high level of parasite population homology by quantification of Plasmodium falciparum alleles in matched peripheral, placental, and umbilical cord blood samples. J Clin Microbiol (2005) 1.05
Maternal anemia at first antenatal visit: prevalence and risk factors in a malaria-endemic area in Benin. Am J Trop Med Hyg (2012) 1.05
PftetQ and pfmdt copy numbers as predictive molecular markers of decreased ex vivo doxycycline susceptibility in imported Plasmodium falciparum malaria. Malar J (2013) 1.05
Is chloroquine chemoprophylaxis still effective to prevent low birth weight? Results of a study in Benin. Malar J (2007) 1.04
First malaria infections in a cohort of infants in Benin: biological, environmental and genetic determinants. Description of the study site, population methods and preliminary results. BMJ Open (2012) 1.04
Expression of the domain cassette 8 Plasmodium falciparum erythrocyte membrane protein 1 is associated with cerebral malaria in Benin. PLoS One (2013) 1.03
The NTS-DBL2X region of VAR2CSA induces cross-reactive antibodies that inhibit adhesion of several Plasmodium falciparum isolates to chondroitin sulfate A. J Infect Dis (2011) 1.02
Chloroquine-resistant malaria in travelers returning from Haiti after 2010 earthquake. Emerg Infect Dis (2012) 1.01
High rates of parasite recrudescence following intermittent preventive treatment with sulphadoxine-pyrimethamine during pregnancy in Benin. Malar J (2013) 1.01
Role of environment and behaviour in familial resemblances of Plasmodium falciparum infection in a population of Senegalese children. Microbes Infect (2004) 1.00
Efficacy of sulfadoxine/pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria in Republic of Congo. Am J Trop Med Hyg (2004) 1.00
Adaptive differentiation of Plasmodium falciparum populations inferred from single-nucleotide polymorphisms (SNPs) conferring drug resistance and from neutral SNPs. J Infect Dis (2010) 1.00
Association of haptoglobin levels with age, parasite density, and haptoglobin genotype in a malaria-endemic area of Gabon. Am J Trop Med Hyg (2006) 1.00
Identification of Id1-DBL2X of VAR2CSA as a key domain inducing highly inhibitory and cross-reactive antibodies. Vaccine (2012) 1.00
Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts < 350 cells/microl. AIDS (2009) 0.99
The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Med (2015) 0.99
A molecular epidemiological study of var gene diversity to characterize the reservoir of Plasmodium falciparum in humans in Africa. PLoS One (2011) 0.98
Low autochtonous urban malaria in Antananarivo (Madagascar). Malar J (2006) 0.98
Impact of red blood cell polymorphisms on the antibody response to Plasmodium falciparum in Senegal. Microbes Infect (2006) 0.97